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Abstract The aim of our study was to test the safety and
tolerability of lithium in multiple system atrophy (MSA).
The study was randomized, placebo-controlled, and dou-
ble-blind. The primary endpoint of the study was safety and
tolerability. An interim analysis, performed 1 year after the
first patient was randomized, showed a higher proportion of
trial abandon (P\ 0.01) and a higher number of adverse
events (P\ 0.02) in the lithium group. The trial was
stopped by the Data Monitoring Committee. Overall, lith-
ium was not well tolerated, and we do not encourage future
studies with lithium in MSA patients.
Keywords Lithium ! Multiple system atrophy ! Clinical
trial ! Safety ! Phase II
Introduction
Multiple system atrophy (MSA) is a rare, sporadic, pro-
gressive neurodegenerative disease presenting with par-
kinsonian features, cerebellar ataxia, autonomic failure,
and corticospinal disorders [1]. The pathological hallmark
of the disease is the formation of oligodendrocyte
cytoplasmic inclusions of fibrillized alpha-synuclein, and
the subsequent induction of apoptosis. It was recently
demonstrated that lithium is able to stimulate autophagy, to
remove protein aggregates [2] including alpha-synuclein
[3], and to slow neurodegeneration and clinical progression
in several animal models [4].
Several trials have been performed with lithium in
neurodegenerative diseases, including amyotrophic lateral
sclerosis and mild cognitive impairment [5–9]. Other trials
are currently ongoing in Alzheimer’s disease, spinocere-
bellar ataxias, progressive supranuclear palsy, corticobasal
degeneration, stroke, and primary progressive multiple
sclerosis (www.clinicaltrials.gov).
Considering the previous points, we decided to test the
safety and tolerability of lithium in MSA in a 48-week,
randomized, placebo-controlled, pilot trial.
Methods
The primary endpoint of the study was the number and
frequency of serious and non-serious adverse events (AEs).
Secondary endpoints were disease progression and quality
of life, and were assessed by a blinded rater. Disease
progression was assessed with the Unified Multiple System
Atrophy Rating Scale (UMSARS) [10], and with magnetic
resonance spectroscopy. Quality of life was assessed using
the EQ-5D, and depression with the Beck’s Depression
Inventory (BDI-II) [11]. Inclusion criteria were: clinical
diagnosis of probable MSA [12], age[18 years. Exclusion
criteria were: cardiomyopathy, nephropathy, hepatopathy,
thyroid dysfunction, sick sinus syndrome, hyposodemia,
pregnancy and/or breastfeeding, treatment with diuretics,
ACE inhibitors, NSAIDs, corticosteroids, aminophylline,
and mannitol.
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The Ethics Committee approved the clinical trial, and it
was registered at www.clinicaltrials.gov (NCT00997672).
Patients were enrolled at the Department of Neurological
Sciences of the Federico II University of Naples, Italy.
A Data Monitoring Committee (DMC) analysis was plan-
ned 1 year after the first randomized patient.
Lithium was administered starting from 150 mg twice-
daily. The dose was increased until serum lithium levels
reached 0.9–1.2 mmol/L. The maximum allowed dose was
1,500 mg/day. Randomization was performed at our study
center using kit number as a randomization number, with a
first-in first-out method. An independent pharmacist, using
a table of random numbers, assembled the randomization
list in blocks of two.
Twenty patients were planned for the trial. Samples size
was not calculated, as the trial was intended as an
exploratory study. Statistical analysis of number and
duration of adverse events, baseline UMSARS, BDI-II,
EQ-5D, age and age at onset, disease duration was con-
ducted with the Mann–Whitney test. Fisher’s exact test was
used to compare gender distribution between groups. Sur-
vival analysis was performed with the logrank (Mantel–
Cox) test in order to evaluate the rate of abandon/death in
lithium and placebo groups. We considered P values less
than 0.05 to be statistically significant. Analysis was per-
formed using SPSS software version 18.0.3 for Mac OSX
(IBM, Chicago, USA).
Results
Ten patients were enrolled, nine were randomized, four
received lithium, and five received placebo (Fig. 1).
None of the baseline variables was significantly different
across treatment (Table 1). All patients presented at onset
with a predominance of cerebellar ataxia (MSAc). They
developed parkinsonian features during disease progres-
sion. Duration of experimental treatment, serum lithium
at last visit, and reason for exclusion are shown in
Table 1.
One year after the first patient was randomized, an
interim analysis was performed by an independent DMC,
with the final decision to stop the trial. Death and trial
abandon were considered the same event in the survival
analysis that showed a proportion of trial abandon/death of
100 % (4/4) in the lithium and 20 % (1/5) in the placebo
group (P\ 0.01). After correction for treatment duration,
the number of AEs was higher in the lithium group (58.4
vs. 21; P\ 0.02). Mean duration of AEs was higher in the
lithium group, but it did not reach significance (59 ± 43
vs. 36 ± 41 days; P = 0.072).
Discussion
The trial was stopped because the number of AEs (primary
endpoint) was higher in the lithium group. This reached
statistical significance 1 year after the first patient was
randomized to treatment (class II evidence). At that point
half of the planned patients had been enrolled. High drop-
out and elevated death rates are constant findings in clinical
trials in MSA [13, 14]. Nevertheless, AEs to lithium forced
all of the treated patients to abandon the trial prematurely.
Of the AEs leading to discontinuation, daytime sleepi-
ness and tremor were related to the study drug by the
investigator. Both are known side effect of lithium. The
remaining AEs were considered as not related, but still
forced patients to discontinue the trial.
No conclusions can be drawn on the effects of lithium
on secondary endpoints of the study, since no treated
patient reached the 24-week checkpoint when clinical re-
assessment was planned.
Limitation of the study is small sample size of nine
randomized patients. This may have determined uneven
distribution of AEs due to random variation. Taking into
account these limitations, we do not encourage future
studies with lithium in MSA patients. Alternative treat-
ments should be used if comorbidity of psychiatric disor-
ders occurs in MSA.
Fig. 1 Study flow-chart
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